KannaLife Sciences, Inc.

11 articles with KannaLife Sciences, Inc.

• Medical Marijuana, Inc. Portfolio Company Kannalife, Inc. Publishes New Research on CBD and Chemotherapy-Induced Peripheral Neuropathy

  5/23/2019

  Medical Marijuana, Inc. announced that the Company's portfolio company Kannalife, Inc., a biopharmaceutical company leading innovation in research, development and discovery of natural and novel biomimetic cannabinoid therapeutic agents, published its research findings around Chemotherapy-Induced Peripheral Neuropathy in the Journal of Molecular Neuroscience.

• Medical Marijuana, Inc. Portfolio Company Kannalife Announces Completion of Name Change, Ticker Symbol Change

  1/17/2019

  Medical Marijuana, Inc., announced that its portfolio company Kannalife, Inc., has announced the company's name change from TYG Solutions Corp. to Kannalife, Inc. and the change of ticker symbol to "KLFE."

• 

  DEA Reclassifies GW Pharmaceuticals’ Epidiolex as a Schedule V Drug

  9/28/2018

  The DEA has reclassified GW Pharmaceutical’s cannabidiol epilepsy treatment Epidiolex as a Schedule V product, which will clear the way for commercialization within the next six weeks.

• Medical Marijuana, Inc. Portfolio Company Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions

  8/1/2018

  Medical Marijuana, Inc. announced that its portfolio company Kannalife Sciences, Inc. has completed a share exchange offer with TYG Solutions Corp.

• Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions Corp.

  8/1/2018

  Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is pleased to announce the completion of a share exchange transaction with TYG Solutions Corp. (OTC: TYYG).

• 

  Cannabis-Based Drug Developers Are Hopeful as FDA Approves First Marijuana-based Seizure Treatment

  6/26/2018

  In a first of its kind ruling, the U.S. Food and Drug Administration approved GW Pharmaceuticals’ Epidiolex, a cannabis-based treatment for seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

• KannaLife Sciences, Inc. Discusses Orphan Drug Opportunity For KLS-13019

  8/11/2015

• KannaLife Sciences, Inc. Announces Publication of Its Global PCT Patent Covering Cannabidiol-like Neuroprotective Agents

  8/6/2015

• KannaLife Sciences, Inc. Announces The Addition Of Dr. Bennet Omalu, Renowned Pathologist And Founder Of Chronic Traumatic Encephalopathy, To Its Scientific Advisory Board

  3/4/2015

• KannaLife Sciences, Inc. Files PCT Patent Application For Novel Treatments for Neurodegenerative Disorders

  1/23/2015

• KannaLife Sciences, Inc. Signs New License Agreement With National Institutes of Health (NIH) For Treatment Of Chronic Traumatic Encephalopathy

  8/4/2014